engages in the discovery, development, manufacture, and marketing of medical therapies and treatments worldwide. Its Prescription Pharmaceuticals segment offers NASONEX for nasal allergy symptoms and nasal polyps; CLARINEX for allergic rhinitis; FORADIL AEROLIZER for asthma and chronic obstructive pulmonary disease; ASMANEX TWISTHALER for asthma; PROVENTIL for the relief of bronchospasm; AVELOX for respiratory and skin infections; CIPRO for respiratory, skin, and urinary tract infections; ELOCON, a topical steroid; and REMICADE for rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, psoriatic arthritis, and psoriasis. It also offers PEG-INTRON for chronic hepatitis C; INTRON A for chronic hepatitis B and C; TEMODAR for brain tumors; CAELYX for ovarian, sarcoma, and metastatic breast cancer; NOXAFIL for fungal infections and oropharyngeal candidiasis; INTEGRILIN for coronary syndrome; SUBUTEX for opiate addiction; and ZETIA and VYTORIN used to lower cholesterol. The company's Consumer Health Care segment provides CLARITIN branded antihistamines; DRIXORAL branded cold and allergy, allergy sinus, flu, and nasal decongestant tablets; AFRIN a nasal decongestant spray; CORRECTOL branded laxatives; foot care products; topical antifungal products; and sun care lotions and sunless tanning products. Schering-Plough's Animal Health segment offers bovine and swine antibiotics, anti-inflammatory products, and vaccines; coccidiosis vaccines for poultry; steroids, anti-inflammatory/analgesics, and topical insecticides for dogs; pet recovery services; parasiticide for sea lice in salmon; and antibiotic for farm-raised fish. The company has strategic alliances with Novartis AG; ALK-Abello; Valeant Pharmaceuticals International; Metabasis Therapeutics, Inc.; Anacor Pharmaceuticals; Santarus, Inc.; and Centocor, Inc. Schering-Plough was founded in 1928 and is headquartered in Kenilworth, New Jersey.
Annotated chart by ClayTrader
Schering-Plough spent $2.2M to lobby
February 27, 2008: 04:43 PM EST
WASHINGTON (AP) - Pharmaceutical company Schering-Plough (NYSE:SGP PRB) (NYSE:SGP) Corp. spent nearly $2.2 million last year to lobby the U.S. government.
The company spent nearly $1.2 million in the second half of 2007 to lobby Congress, according to a disclosure form posted online Feb. 14 by the Senate's public records office. It lobbied on labeling and various appropriations bills.
Schering-Plough spent $980,000 in the first six months of 2007 to lobby on similar issues.
Lobbyists are required to disclose activities that could influence members of the executive and legislative branches, under a federal law enacted in 1995.
WESTON, FL, Feb 27, 2008 (MARKET WIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning are: China Health Management Corp. (PINKSHEETS: CNHC), RadioShack Corporation (NYSE: RSH: 18.17, -1.06, -5.51%), Pfizer Inc. (NYSE: PFE: 22.55, -0.20, -0.87%) and Schering-Plough Corporation (NYSE: SGP: 21.97, -0.13, -0.58%).
Investors should have a close eye on China Health Management Corp. (PINKSHEETS: CNHC), as the company has made some major announcements recently. Aside from Monday's press release announcing that its Richland International Hospital (RIH) has implemented Traditional Chinese Medicine as part of its diagnosis and treatment programs, the company has also announced that RIH has signed a $1.15USD million contract with OLYMPUS to set up the first Minimally Invasive Operating Theatre in China.
This could be very big news! Minimal invasive surgery has come into wide use during surgical procedures in a variety of clinical disciplines, including general surgery, ear, nose and throat surgery, gynecological, urology, neuro, pediatric and thoracic surgery. The company believes that greater use of endoscopes in surgical procedures will not only help to shorten hospital stays and alleviate burden on patients, but will also contribute to greater efficiency in healthcare.
OLYMPUS' minimally invasive diagnosis and treatment products for endoscopic surgery enable effective medical procedures and treatments without open abdominal surgery. These factors include improved image quality through the advent of high-resolution imaging, as well as OLYMPUS' development of a broad lineup of endotherapy products, treatment equipment and endoscopic surgery apparatus.
This could be a huge breakthrough for the company.
The stock closed Tuesday at Fifty Eight cents a share.
For Wall Street News Alert's in-depth profile of China Health Management Corp., visit http://www.WallStreetNewsAlert.com/HotStocks/CNHC022608/default.aspx
To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.
RadioShack Corporation (NYSE: RSH: 18.17, -1.06, -5.51%) up 21.5% on 16 million shares traded.
RadioShack Corporation is one of the nation's most experienced and trusted consumer electronics specialty retailers.
Pfizer Inc. (NYSE: PFE: 22.55, -0.20, -0.87%) up 0.2% on 39.6 million shares traded.
Founded in 1849, Pfizer is the world's largest research-based pharmaceutical company taking new approaches to better health. The company discovers, develops, manufactures and delivers quality, safe and effective prescription medicines to treat and help prevent disease for both people and animals.
Schering-Plough Corporation (NYSE: SGP: 21.97, -0.13, -0.58%) up 1.1% on 15.6 million shares traded.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world.